Academic literature on the topic 'Modèle de progression de la maladie'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Modèle de progression de la maladie.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Modèle de progression de la maladie"
de Pontual, Laure, Geneviève Gourdon, and Stéphanie Tomé. "Identification de nouveaux facteurs entraînant des contractions CTG.CAG dans la dystrophie myotonique de type 1." médecine/sciences 37 (November 2021): 6–10. http://dx.doi.org/10.1051/medsci/2021182.
Full textCherqui, Stéphanie. "Cystinose." médecine/sciences 39, no. 3 (March 2023): 253–61. http://dx.doi.org/10.1051/medsci/2023025.
Full textFrazier, Leslie D. "William J. Weiner, Lisa M. Shulman, and Anthony E. Lang Parkinson's disease: A complete guide for patients and families. Baltimore, MD: Johns Hopkins University Press, 2001." Canadian Journal on Aging / La Revue canadienne du vieillissement 21, no. 2 (2002): 317–19. http://dx.doi.org/10.1017/s0714980800001598.
Full textSt-Arnaud, M., and P. Neumann. "Un modèle d’estimation de l’état d’avancement de la période d’infection primaire par le Venturia inaequalis en verger de pommiers." Phytoprotection 71, no. 2 (April 12, 2005): 73–84. http://dx.doi.org/10.7202/705985ar.
Full textKelner, Merrijoy. "Unraveling the Mystery of Health: How People Manage Stress and Stay Well. Aaron Antonovsky. Jossey-Bass Publishers, San Francisco, 1987. $35.00." Canadian Journal on Aging / La Revue canadienne du vieillissement 7, no. 1 (1988): 77–79. http://dx.doi.org/10.1017/s0714980800007133.
Full textBoucquemont, J., M. Metzger, C. Combe, B. Stengel, and K. Leffondré. "Quels modèles statistiques utiliser pour étudier les facteurs de risque de progression de la maladie rénale chronique ?" Néphrologie & Thérapeutique 10, no. 5 (September 2014): 267. http://dx.doi.org/10.1016/j.nephro.2014.07.318.
Full textSerra, Éric. "Fibromyalgie, maladie ou modèle." Douleurs : Evaluation - Diagnostic - Traitement 10 (February 2009): S73—S78. http://dx.doi.org/10.1016/j.douler.2008.12.024.
Full textLaugier, A. "Une maladie modèle en oncologie." Cancer/Radiothérapie 3, no. 2 (March 1999): 99–104. http://dx.doi.org/10.1016/s1278-3218(99)80039-0.
Full textToussaint, J., T. Habtemariam, D. Oryang, and S. Wilson. "Développement d’un modèle de simulation informatique pour l’anaplasmose, notamment dans les Antilles." Revue d’élevage et de médecine vétérinaire des pays tropicaux 46, no. 1-2 (January 1, 1993): 47–48. http://dx.doi.org/10.19182/remvt.9396.
Full textKahn, A. "Des modèle murins de maladie d'Alzheimer." médecine/sciences 7, no. 8 (1991): 859. http://dx.doi.org/10.4267/10608/4466.
Full textDissertations / Theses on the topic "Modèle de progression de la maladie"
Boucquemont, Julie. "Modèles statistiques pour l'étude de la progression de la maladie rénale chronique." Thesis, Bordeaux, 2014. http://www.theses.fr/2014BORD0411/document.
Full textThe objective of this thesis was to illustrate the benefit of using advanced statistical methods to study associations between risk factors and chrouic kidney disease (CKD) progression. In a first time, we conducted a literature review of statistical methods used to investigate risk factors of CKD progression, identified important methodological issues, and discussed solutions. In our sec ond work, we focused on survival analyses and issues with interval-censoring, which occurs when the event of interest is the progression to a specifie CKD stage, and competing risk with death. A comparison between standard survival models and the illness-death mode! for interval-censored data allowed us to illustrate the impact of modeling on the estimates of both the effects of risk factors and the probabilities of events, using data from the NephroTest cohort. Other works fo cused on analysis of longitudinal data on renal function. We illustrated the interest of linear mixed mode! in this context and presented its extension to account for sub-populations with different trajectories of renal function. We identified five classes, including one with a strong decline and one with an improvement of renal function over time. Severa! perspectives on predictions bind the two types of analyses presented in this thesis
Couronné, Raphaël. "Modélisation de la progression de la maladie de Parkinson." Electronic Thesis or Diss., Sorbonne université, 2021. http://www.theses.fr/2021SORUS363.
Full textIn this work, we developed statistical methods to model disease progression from patient’s repeated measurements, with a focus on Parkinson’s Disease (PD). A key challenge lies in the inherent heterogeneity of PD across patients, to the extent that PD is now suspected to encompass multiple subtypes or motor phenotypes. To gain insights on disease progression, research studies propose to gather a broad range of marker measurements, at multiple timepoints for each patients. These data allow to investigate the disease’s patterns of progression via statistical modeling. In a first part, we modeled the progression of scalar markers of PD. We extended on a disease progression model, namely the longitudinal spatiotemporal model. We then proposed to address data missingness, and to model the joint progression of markers of different nature, such as clinical scores, and scalar measurements extracted on imaging modalities. With this method, we modeled early motor progression in PD, and, in a second work, the heterogeneity of idiopathic PD progression, with a focus on sleep symptoms. In a second, independent, part of the manuscript, we tackled the longitudinal modeling of medical images. For these higher dimensionality data, Deep Learning is often used, but mostly in cross sectional setups, ignoring the possible inner dynamics. We proposed to leverage Deep Learning as a dimensionality reduction tool to build a spatiotemporal coordinate system of disease progression. We first took advantage of this flexibility to handle multimodal data. Then we leveraged the self-supervision induced by assuming monotonicity over time, to offer higher flexibility in modeling temporal variability
Sauty, Benoît. "Multimodal modelling of Alzheimer's Disease progression." Electronic Thesis or Diss., Sorbonne université, 2023. http://www.theses.fr/2023SORUS348.
Full textAlzheimer's disease (AD) is a multi-facet pathology, that can be monitored through a variety of data types. This thesis aims to leverage multimodal longitudinal data, especially imaging scans and cognitive tests, to provide a statistical description of the progression of AD and to enable individual forecasting of future decline. Mixed-effect disease progression models (DPMs) are commonly used for these tasks. In this context, our first contribution questions the frequent assumption that biomarkers follow linear or logistic functions over time, and we propose a geometric framework that assumes the data lie on a manifold and follow geodesics over time. We learn the Riemannian metric of the observation space and are able to model a wider variety of biomarkers, without priors on the shape of the trajectory over time. Using variational auto-encoders, we then extend this framework to neuroimaging data (MRI or PET scans), in order to provide high-dimensional progression models that describe the patterns of structural and functional alterations of the brain over the course of AD. We then apply this family of DPMs to clinical studies data in order to investigate the heterogeneity of AD progression, due to APOE-e4 genotype and sex on patterns of brain alterations. Lastly, we use said DPMs with a set of imaging and fluid biomarkers to identify the specific combinations of input features that best forecast cognitive declines in patients at different stages of the disease. The thesis demonstrates that DPMs can effectively model the progression of AD using a great variety of multimodal longitudinal data and provide valuable insights into the disease's clinical manifestations and progression. These findings can inform clinical trial design and facilitate more accurate prognosis and individualized treatment strategies for patients with AD
Buatois, Simon. "Novel pharmacometric methods to improve clinical drug development in progressive diseases." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCC133.
Full textIn the mid-1990, model-based approaches were mainly used as supporting tools for drug development. Restricted to the “rescue mode” in situations of drug development failure, the impact of model-based approaches was relatively limited. Nowadays, the merits of these approaches are widely recognised by stakeholders in healthcare and have a crucial role in drug development for progressive diseases. Despite their numerous advantages, model-based approaches present important drawbacks limiting their use in confirmatory trials. Traditional pharmacometric (PMX) analyses relies on model selection, and consequently ignores model structure uncertainty when generating statistical inference. The problem of model selection is potentially leading to over-optimistic confidence intervals and resulting in a type I error inflation. Two projects of this thesis aimed at investigating the value of innovative PMX approaches to address part of these shortcomings in a hypothetical dose-finding study for a progressive disorder. The model averaging approach coupled to a combined likelihood ratio test showed promising results and represents an additional step towards the use of PMX for primary analysis in dose-finding studies. In the learning phase, PMX is a key discipline with applications at every stage of drug development to gain insight into drug, mechanism and disease characteristics with the ultimate goal to aid efficient drug development. In this thesis, the merits of PMX analysis were evaluated, in the context of Parkinson’s disease. An item-response theory longitudinal model was successfully developed to precisely describe the disease progression of Parkinson’s disease patients while acknowledging the composite nature of a patient-reported outcome. To conclude, this thesis enhances the use of PMX to aid efficient drug development and/or regulatory decisions in drug development
Sautière, Pierre-Éric. "Mise au point d'un modèle cellulaire de dégénérescence neurofibrillaire de type alzheimer." Lille 1, 1994. http://www.theses.fr/1994LIL10012.
Full textPeyre, Matthieu. "Modélisation de la tumorigenèse méningée chez la souris : progression tumorale liée à Nf2 et Cdkn2ab et voies alternatives d'oncogenèse." Paris 7, 2013. http://www.theses.fr/2013PA077109.
Full textMeningioma is the most common primary nervous System tumor. Although most tumors are benign , they can recur even after total resection, present with significant morbidity and there is a growing proportion, up to 30%, of aggressive variants (WHO grade II and III). The creation of relevant genetically engineered mouse models is the cornerstone of future advances in meningioma treatment through pre-clinical testing and thorough dissection of molecular mechanisms of tumorigenesis. We here present the creation and characterization in vivo and in vitro of two new genetically engineered mouse models of meningioma : one model of Grade ll-lll meningioma through bi-allelic A//2 inactivation and homozygous Cdkn2ab deletion and one model of PDGF-(3-induced meningioma, with or without bi-allelic A//2 inactivation. On the basis of recent whole genome studies, we also set the bases of two future A//2-independant GEM meningioma models through Akt and Smo activation. The establishment of mouse meningioma cell lines and a syngenic orthotopic meningioma mouse model allowed the evaluation of a new handheld confocal imaging device and will eventually lead to future « co-trials »
Tabbekh, Mouna. "Rôle de CD5 dans la potentialisation de la réponse T cytotoxique et dans le contrôle de la progression tumorale dans un modèle in vivo." Thesis, Paris 11, 2011. http://www.theses.fr/2011PA11T026.
Full textA major challenge in tumor immunology is based on effective and prolonged induction of the effectorphase of antitumor immune response. A better understanding of the mechanisms involved in potentiatingthe antitumor activity of immune effectors, particularly the CTL infiltrating the tumor represents aconsiderable challenge in developing new approaches to immunotherapy. In this context we areparticularly interested in studying the role of CD5 in the control of tumor progression, particularly inpotentiating the cytotoxic activity of CTLs infiltrating B16 melanoma. Our results showed a significantdelay in tumor growth in CD5-/- mice as compared with wild type mice. The control of tumor growth inCD5-/- mice does not seem to correlate with a higher recruitment of T cells, but with increased cytotoxicityof infiltrating T cells against B16 cells. We have also shown that this response is transient and that thetumor escape from immune system takes place at a later stage of tumor progression. This tumor escapeappears to be associated with increased death by AICD of TIL CD8+ from CD5-/- mice as compared withTIL CD8+ from wild type mice wich correlated with the induction of FasL on the surface of TIL. In vivomodulation of Fas/FasL with an adenovirus AdFas-Fc protects tumor infiltrating T CD8+/CD5- fromapoptosis and thereby prevents the tumor escape. In addition, analysis of specific T lymphocyte repertoirein CD5-/- mice suggests that the control of tumor progression could be linked to a greater in situproliferation of specific CD5- T lymphocytes. Our results also show that immunization of CD5-/- miceusing different melanoma associated antigens contributes to the potentiation of antitumor immuneresponse. All these results highlight a particular interest in targeting of CD5 to improve currentapproaches to tumor immunotherapy
Pineau, sandra. "Etude de l'implication des microARNs dans la progression tumorale grâce au modèle réversible de la transformation leucocytaire induite par Theileria." Paris 7, 2011. http://www.theses.fr/2011PA077133.
Full textThe acquisition and maintenance of cellular identity involve an equilibrium between proliferation and differentiation. Imbalance between those two states can result in different types of diseases, including cancer. Tumor progression is a multistep process in which genetic and epigenetic modifications sequentially alter gene expression. To examine the impact of these mechanisms, we are studing a unique model of reversible bovine leukocyte transformation induced by an intracellular eukaryotic parasite: Theileria. Bovine leukocytes infected with Theileria exhibit a cancerous phenotype, but when the parasite is eliminated cells enter quiescence or apoptosis. We describe a three-partner positive feedback loop. We show that the microRNA-155 represses the expression of the protein DET1, a member of the COP1 complex which ubiquitinates c-Jun. We show that AP-1 activates thé expression of BIC which contains miR-155. This loop maintains the miR-155 and AP-1 action on their target genes and stimulates cell proliferation. Finally, we demonstrate that the deregulation of any loop member alters the expression of the two other members and leads to apoptosis. We have identified a new target of the microRNA let-7: Polycomb protein EZH2. EZH2 and let-7 expression were inversely correlated ; LIN28 expression, a let-7 post-transcriptional repressor, was correlated with EZH2 expression in models of cancer and cell differentiation. My results suggest a direct inhibition of EZH2 expression by let-7, correlates with of EZH2 target genes including ADRB2 protein involved in invasive processes. I also showed that let-7 overexpression in transformed cells decreased the invasive capacity
Delacôte, Claire. "Vers une meilleure compréhension de la maladie du foie liée à l'alcool et des facteurs influençant sa progression : approche de modélisation." Thesis, Lille 2, 2020. http://www.theses.fr/2020LIL2S029.
Full textIn France, excessive alcohol consumption is the leading cause of cirrhosis and hepatocellular carcinoma (HCC), ahead of viral hepatitis and metabolic syndrome. In 2016, there were nearly 10,500 deaths by cirrhosis or HCC, despite a significant decrease in per capita alcohol consumption since 1960 (26L in 1960, 11.7L in 2017).Alcohol drinkers are at risk of developing alcohol-related liver disease (ALD). It progresses from the initial stage of steatosis to more advanced stages of fibrosis and cirrhosis, which may lead to complications: decompensation and HCC. ALD is an asymptomatic disease prior to the onset of complications, and many patients are diagnosed late with life-threatening consequences.Implementing early actions targeting excessive alcohol drinkers could help to reduce liver morbidity and mortality through the avoidance or earlier diagnosis of complications. The evaluation of the possible benefit of such public health actions requires, on the one hand, knowledge of the different stages leading to the development of complications and, on the other hand, knowledge of the impact of risk factors on progression, in order to be able to determine the populations to target. Among the risk factors identified, the metabolic syndrome plays an important role. Thus, in order to understand the mechanisms of evolution of ALD, it is necessary to study in parallel those leading to non-alcoholic fatty liver disease (NAFLD).The natural history of ALD is still poorly described, especially for the stages preceding cirrhosis. Mathematical modeling provides a conceptual framework to overcome the ethical issues that would arise from a cohort study of the evolution of ALD.The main objective of this work is to mathematically reconstruct the natural history of ALD and to predict the associated morbidity and mortality. The secondary objectives are to estimate the incidence of this pathology and to identify the at-risk population. For this purpose, we developed a Markov model that simulates the trajectory of cohorts of individuals from the moment they start at-risk alcohol consumption until their death. It integrates the main risk factors described as associated with the progression of ALD in the literature (sex, age, overweight and obesity, amount of alcohol, genetic polymorphism). Unknown parameters of progression are estimated by a back-calculation method.Three steps were necessary to supply and calibrate this model : 1) characterize mortality by decompensated cirrhosis and HCC related to alcohol consumption or metabolic syndrome from data provided by the French National Hospital Discharge database; 2) set up a Markov model on hospitalization data of excessive consumers to estimate the progression of fibrosis; 3) implement a Markov model on survey data from the general French population to estimate the process of entry into at-risk alcohol consumption or the onset of overweight and obesity.In conclusion, this work is the first to characterize the progression of ALD in the general French population. It is based on robust epidemiological data to which new insights are provided. The developed tools could be used to test the impact of public health policies that could be implemented in populations most likely to develop liver damage
Kmetzsch, Virgilio. "Multimodal analysis of neuroimaging and transcriptomic data in genetic frontotemporal dementia." Electronic Thesis or Diss., Sorbonne université, 2022. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2022SORUS279.pdf.
Full textFrontotemporal dementia (FTD) represents the second most common type of dementia in adults under the age of 65. Currently, there are no treatments that can cure this condition. In this context, it is essential that biomarkers capable of assessing disease progression are identified. This thesis has two objectives. First, to analyze the expression patterns of microRNAs taken from blood samples of patients, asymptomatic individuals who have certain genetic mutations causing FTD, and controls, to identify whether the expressions of some microRNAs correlate with mutation status and disease progression. Second, this work aims at proposing methods for integrating cross-sectional data from microRNAs and neuroimaging to estimate disease progression. We conducted three studies. Initially, we focused on plasma samples from C9orf72 expansion carriers. We identified four microRNAs whose expressions correlated with the clinical status of the participants. Next, we tested all microRNA signatures identified in the literature as potential biomarkers of FTD or amyotrophic lateral sclerosis (ALS), in two groups of individuals. Finally, in our third work, we proposed a new approach, using a supervised multimodal variational autoencoder, that estimates a disease progression score from cross-sectional microRNA expression and neuroimaging datasets with small sample sizes. The work conducted in this interdisciplinary thesis showed that it is possible to use non-invasive biomarkers, such as circulating microRNAs and magnetic resonance imaging, to assess the progression of rare neurodegenerative diseases such as FTD and ALS
Books on the topic "Modèle de progression de la maladie"
Michaud, Annie. Le travail social sous la tactique du modèle médical: Une perspective postmoderniste de la maladie mentale. Sudbury, Ont: Université Laurentienne, 2005.
Find full textJohansen, Bruce, and Adebowale Akande, eds. Nationalism: Past as Prologue. Nova Science Publishers, Inc., 2021. http://dx.doi.org/10.52305/aief3847.
Full textBook chapters on the topic "Modèle de progression de la maladie"
Gianfrancesco, Angelo. "Morbus Animae: des vices monastiques à la morbidité sociale et à l’aliénation mentale, évolution et transformation du modèle monastique de la maladie de l’âme." In Saint-Victor de Marseille. Études archéologiques et historiques, 187–211. Turnhout: Brepols Publishers, 2009. http://dx.doi.org/10.1484/m.bat-eb.3.1381.
Full textHugentobler, Valérie. "La « colocation Alzheimer ». Un modèle d’habitat alternatif." In La sociologie face à la maladie d’Alzheimer, 111–30. Presses universitaires du Septentrion, 2023. http://dx.doi.org/10.4000/books.septentrion.145434.
Full text"11. Modélisation de la progression de la maladie." In Voyage au coeur de la relation dose-réponse du médicament, 195–96. EDP Sciences, 2020. http://dx.doi.org/10.1051/978-2-7598-1999-7.c015.
Full textTroubé, Sarah, and Arnaud Plagnol. "Chapitre 2. Limites du modèle de la maladie et apports psychodynamiques." In Les nouveaux modèles de soins, 19–30. Doin, 2018. http://dx.doi.org/10.3917/jle.plagn.2018.01.0019.
Full textDelgoulet, Catherine. "Que sait‐on du travail ?" In Que sait‐on du travail ?, 114–27. Presses de Sciences Po, 2023. http://dx.doi.org/10.3917/scpo.colle.2023.01.0114.
Full textBAUDRY, Anne-Sophie, and Véronique CHRISTOPHE. "Les compétences émotionnelles au cœur de l’ajustement face au cancer." In Le patient et son entourage, 9–24. Editions des archives contemporaines, 2023. http://dx.doi.org/10.17184/eac.7284.
Full textConference papers on the topic "Modèle de progression de la maladie"
Chimpololo, Andrew. "Using the Five-Stage Model to Examine Capacity Building of Teaching Staff on Emergency Education in the Covid-19 Era at a Malawian University." In Tenth Pan-Commonwealth Forum on Open Learning. Commonwealth of Learning, 2022. http://dx.doi.org/10.56059/pcf10.4633.
Full textESSAFI, Mokhtar, and Éric BARGET. "Les programmes d’activité physique en entreprise : la nécessité d’une approche pluridisciplinaire." In Les journées de l'interdisciplinarité 2023. Limoges: Université de Limoges, 2024. http://dx.doi.org/10.25965/lji.785.
Full text